A value‐based healthcare model for initiating and switching psoriasis therapies—Results from the prospective multicentre IMPROVE study

Author:

Nielsen V. W.1ORCID,Johansen C. B.1ORCID,Todberg T.2ORCID,Skov L.23ORCID,Nissen C. V.1ORCID,Dodge R.4,Egeberg A.13ORCID,Thyssen J. P.13ORCID,Thomsen S. F.15ORCID

Affiliation:

1. Department of Dermato‐Venereology & Wound Healing Centre, Bispebjerg Hospital University of Copenhagen Copenhagen Denmark

2. Department of Dermatology and Allergy, Herlev and Gentofte Hospital University of Copenhagen Copenhagen Denmark

3. Department of Clinical Medicine University of Copenhagen Copenhagen Denmark

4. Novartis Healthcare A/S Copenhagen Denmark

5. Department of Biomedical Sciences University of Copenhagen Copenhagen Denmark

Abstract

AbstractBackgroundLittle is known about the therapeutic benefits of a value‐based healthcare model compared to a traditional activity‐based incentive model in psoriasis (PsO).ObjectivesThis prospective non‐interventional study evaluated an outcome‐based, patient‐centred management model for patients with PsO.MethodsIn total, 49 patients with a Psoriasis Area and Severity Index (PASI) ≥3 who were starting or switching between treatments were included. Patients were assessed at baseline, 3 and 9 months. The patient benefit index (PBI) was calculated using predefined questionnaires. An expected PBI was calculated and adjusted for risk factors known to complicate treatment, that is overweight and smoking. The model remunerated the department on whether the observed PBI exceeded the expected PBI to incentivize over‐performance.ResultsIn total, 40 patients (80%) completed all three visits; 32.7% were smokers and 73.5% were overweight. Mean PASI at baseline was 11.5 (SD 9.1); PASI improved significantly from baseline through 3 months: mean reduction, 8.0 (SD 9.2), p < 0.001 and was maintained until 9 months: mean further reduction, 0.1 (SD 3.3), p = 0.893. The mean PBI was 2.5 (SD 1.3) and 2.8 (SD 1.1) at 3 and 9 months, respectively. A PBI ≥1 was achieved by 87.8% at 3 and 95.1% at 9 months. Overall, the department was remunerated a mean 2721.1 DKK (SD 4472.8) per patient. In subgroup analysis, the department was remunerated a mean of, respectively, 2428.6 (SD 5089.5), 2636.6 (SD 4471.3) and 3196.5 (SD 4497.1) DKK for patients with none, 1 or 2 risk factors, that is smoking or/and overweight.ConclusionsThe model evaluated herein is the first value‐based model to calculate remuneration from patient reported outcomes and showed to successfully predict the expected PBI and remunerate treatment based on whether the expected treatment goal was met or exceeded. This can be utilized in the patient‐centred management of PsO.

Publisher

Wiley

Subject

Infectious Diseases,Dermatology

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

1. Balancing outcomes and costs for best value in psoriasis;Journal of the European Academy of Dermatology and Venereology;2024-04-25

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3